Atlas Trials

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

Clinical trial NCT05753592 · COMPLETED

Trial details

NCT number
NCT05753592
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic Impairment
Start date
2022-10-31
Primary completion
2023-12-14
Enrollment
38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.